BC Week In Review | Jun 10, 2013
Clinical News

Almitrine-containing medicines regulatory update

EMA's Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human (CMDh) endorsed a recommendation from the agency's Pharmacovigilance Risk Assessment Committee (PRAC) to suspend marketing authorization of oral almitrine-containing medicines in the EU. EMA said almitrine...
BC Week In Review | May 27, 2013
Clinical News

Almitrine-containing medicines regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that all marketing authorizations for oral almitrine-containing medicines be withdrawn across the EU after concluding that their benefits no longer outweigh their risks. EMA said almitrine has been...
BC Week In Review | May 27, 2013
Clinical News

Almitrine regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that all marketing authorizations for oral almitrine-containing medicines be withdrawn across the EU after concluding that their benefits no longer outweigh their risks. EMA said almitrine has been...
BioCentury | Oct 15, 2012
Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
Items per page:
1 - 4 of 4